Alev Lazoğlu Ozkaya, Esra Laloğlu, Albulhakim Hasan Gul, N. Çelik
Coronavirus disease 2019 (COVID-19) exhibits variations in terms of patients’ clinical symptoms and levels of routinely employed biochemical markers. The aim of the current study was to determine the correlation between serum levels of the C-X-C chemokine ligand type 12 (CXCL12) and C-X-C chemokine receptor type 4 (CXCR4), one of its specific receptors, and disease severity in COVID-19 patients. Sixty-nine patients were diagnosed with COVID-19 from February to July 2021, and a healthy control group of 39 individuals were enrolled in the study. Patients were divided into subgroups: mild-moderate and severe. Serum CXCL12 and CXCR4 levels were measured using the enzyme-linked immunosorbent assay method. CXCL12 and CXCR4 concentrations were both significantly higher in the clinically severe disease group compared to the mild-moderate disease group (p<0.05 in both groups). CXCL12 and CXCR4 levels were also significantly higher in the patients with clinically mild-moderate disease compared to the control group (p<0.001 and p<0.05, respectively). Both CXCL12 and CXCR4 levels were correlated with clinical severity. Serum CXCL12 and CXCR4 levels were significantly positively correlated. Assuming a cut-off value of 1.44 ng/mL, serum CXCL12 levels showed 98 % sensitivity and 84 % specificity to distinguish between COVID-19 patients and healthy individuals (AUC=0.98, p<0.001, 95 % CI=0.95–1.0). Serum CXCR4 levels distinguished individuals with COVID-19 from healthy controls with 88 % sensitivity and 72 % specificity at a cut-off value of 69.7 pg/mL (AUC=0.82, p<0.001, 95 % CI=0.74–0.9). Serum CXCL12 and CXCR4 levels may be included among the biomarkers used to differentiate patients with COVID-19 and determine the clinical severity of the disease.
{"title":"CXCL12/CXCR4 as a potential axis in diagnosis and predicting disease severity in COVID-19 patients: a new perspective","authors":"Alev Lazoğlu Ozkaya, Esra Laloğlu, Albulhakim Hasan Gul, N. Çelik","doi":"10.1515/tjb-2023-0193","DOIUrl":"https://doi.org/10.1515/tjb-2023-0193","url":null,"abstract":"\u0000 \u0000 \u0000 Coronavirus disease 2019 (COVID-19) exhibits variations in terms of patients’ clinical symptoms and levels of routinely employed biochemical markers. The aim of the current study was to determine the correlation between serum levels of the C-X-C chemokine ligand type 12 (CXCL12) and C-X-C chemokine receptor type 4 (CXCR4), one of its specific receptors, and disease severity in COVID-19 patients.\u0000 \u0000 \u0000 \u0000 Sixty-nine patients were diagnosed with COVID-19 from February to July 2021, and a healthy control group of 39 individuals were enrolled in the study. Patients were divided into subgroups: mild-moderate and severe. Serum CXCL12 and CXCR4 levels were measured using the enzyme-linked immunosorbent assay method.\u0000 \u0000 \u0000 \u0000 CXCL12 and CXCR4 concentrations were both significantly higher in the clinically severe disease group compared to the mild-moderate disease group (p<0.05 in both groups). CXCL12 and CXCR4 levels were also significantly higher in the patients with clinically mild-moderate disease compared to the control group (p<0.001 and p<0.05, respectively). Both CXCL12 and CXCR4 levels were correlated with clinical severity. Serum CXCL12 and CXCR4 levels were significantly positively correlated. Assuming a cut-off value of 1.44 ng/mL, serum CXCL12 levels showed 98 % sensitivity and 84 % specificity to distinguish between COVID-19 patients and healthy individuals (AUC=0.98, p<0.001, 95 % CI=0.95–1.0). Serum CXCR4 levels distinguished individuals with COVID-19 from healthy controls with 88 % sensitivity and 72 % specificity at a cut-off value of 69.7 pg/mL (AUC=0.82, p<0.001, 95 % CI=0.74–0.9).\u0000 \u0000 \u0000 \u0000 Serum CXCL12 and CXCR4 levels may be included among the biomarkers used to differentiate patients with COVID-19 and determine the clinical severity of the disease.\u0000","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"28 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141816835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hilal Şentürk, Huri Dedeakayoğulları, İlke U. Marion, S. Özçubukçu, M. S. Kesici, Şeyma Ünsal Beyge, Muradiye Acar, Merve Erkısa Genel, F. Akbaş, E. Ulukaya
Human estrogen receptor alpha (ERα) is considered an important target, especially in the treatment of breast cancer, as it has a vital role in cancer development. ERα-targeted therapies generally target the ligand binding domain (LBD) of ERα. However, over time, cells develop resistance to this mechanism alternative approaches to inhibit ERα activity target ERα–DNA or ERα–cofactor interactions. Inhibitors of ERα–cofactor interactions are designed by targeting the hydrophobic hollow region of the receptor box LXXLL motif. In this context, helix-stabilized cyclic peptides (SPs) designed with in silico approaches were obtained by solid phase peptide synthesis. The effects of SPs on MCF-7 cells were examined with MTT and ATP, and qPCR and flow cytometry were used for further analysis. Our results demonstrated that the SPs were effective only in MCF-7 cells expressing ERα. In addition, cyclic peptide combinations (SPCs) showed anti-proliferative and toxic effects on MCF-7 cells. The impact of SPCs with the highest inhibitory effect in MCF-7 cells on ERα-related genes and markers of apoptosis was revealed. Moreover, the flow cytometry analysis result used to examine apoptotic cells proved the apoptosis of SPCs in MCF-7 cells. These findings suggest that our novel SPs, which inhibit coactivator interactions of ERα, induce apoptosis of MCF-7 cells. Thus, considering this strong effect of SPs in the inhibition of receptors, it is pointed out that they can be further developed as an alternative to current clinical treatments or as an auxiliary approach in the generating of new targeted peptide-based therapies.
{"title":"Human estrogen receptor alpha (ERα) targeted cyclic peptides inhibit cell growth and induce apoptosis in MCF-7 cells","authors":"Hilal Şentürk, Huri Dedeakayoğulları, İlke U. Marion, S. Özçubukçu, M. S. Kesici, Şeyma Ünsal Beyge, Muradiye Acar, Merve Erkısa Genel, F. Akbaş, E. Ulukaya","doi":"10.1515/tjb-2024-0123","DOIUrl":"https://doi.org/10.1515/tjb-2024-0123","url":null,"abstract":"\u0000 \u0000 \u0000 Human estrogen receptor alpha (ERα) is considered an important target, especially in the treatment of breast cancer, as it has a vital role in cancer development. ERα-targeted therapies generally target the ligand binding domain (LBD) of ERα. However, over time, cells develop resistance to this mechanism alternative approaches to inhibit ERα activity target ERα–DNA or ERα–cofactor interactions. Inhibitors of ERα–cofactor interactions are designed by targeting the hydrophobic hollow region of the receptor box LXXLL motif.\u0000 \u0000 \u0000 \u0000 In this context, helix-stabilized cyclic peptides (SPs) designed with in silico approaches were obtained by solid phase peptide synthesis. The effects of SPs on MCF-7 cells were examined with MTT and ATP, and qPCR and flow cytometry were used for further analysis.\u0000 \u0000 \u0000 \u0000 Our results demonstrated that the SPs were effective only in MCF-7 cells expressing ERα. In addition, cyclic peptide combinations (SPCs) showed anti-proliferative and toxic effects on MCF-7 cells. The impact of SPCs with the highest inhibitory effect in MCF-7 cells on ERα-related genes and markers of apoptosis was revealed. Moreover, the flow cytometry analysis result used to examine apoptotic cells proved the apoptosis of SPCs in MCF-7 cells.\u0000 \u0000 \u0000 \u0000 These findings suggest that our novel SPs, which inhibit coactivator interactions of ERα, induce apoptosis of MCF-7 cells. Thus, considering this strong effect of SPs in the inhibition of receptors, it is pointed out that they can be further developed as an alternative to current clinical treatments or as an auxiliary approach in the generating of new targeted peptide-based therapies.\u0000","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"46 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141640070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Şule Öncül, E. Becer, Pınar Mega Tiber, K. Teralı, A. Aykaç
Cladodes of Opuntia ficus-indica (OFI) are thought to be an excellent source of bioactive compounds, making them an aspirant for the manufacture of health-promoting compounds. This study aims at exploring the pro-apoptotic effects of spiny and thornless OFI cladode extracts on the human immortalized myelogenous leukemia cell line (K562). The ethanol extraction method was used for preparing cladode extract. Cytotoxicity was evaluated by MTT assays. Membrane permeability/damage was detected by annexin V-binding assays, and mitochondrial damage/alteration was detected by mitochondrial membrane potential measurements. The protein expression quantities of Bax and Bcl-2 were assessed by Western blotting. The pro-apoptotic potentials of the main spiny and thornless OFI extract constituents were investigated structurally and mechanistically using protein–ligand docking and interaction profiling. Spiny OFI extract displayed a stronger cytotoxic effect than thornless OFI extract on K562 cells. In silico findings agreed with the pro-apoptotic action observed in vitro. Finally, our findings imply that OFI extracts cause apoptosis in K562 cells in order to have anti-cancer effects.
{"title":"In vitro and in silico investigations of the pro-apoptotic activity of Opuntia ficus-indica cladode extracts against K562 cells","authors":"Şule Öncül, E. Becer, Pınar Mega Tiber, K. Teralı, A. Aykaç","doi":"10.1515/tjb-2023-0229","DOIUrl":"https://doi.org/10.1515/tjb-2023-0229","url":null,"abstract":"\u0000 \u0000 \u0000 Cladodes of Opuntia ficus-indica (OFI) are thought to be an excellent source of bioactive compounds, making them an aspirant for the manufacture of health-promoting compounds. This study aims at exploring the pro-apoptotic effects of spiny and thornless OFI cladode extracts on the human immortalized myelogenous leukemia cell line (K562).\u0000 \u0000 \u0000 \u0000 The ethanol extraction method was used for preparing cladode extract. Cytotoxicity was evaluated by MTT assays. Membrane permeability/damage was detected by annexin V-binding assays, and mitochondrial damage/alteration was detected by mitochondrial membrane potential measurements. The protein expression quantities of Bax and Bcl-2 were assessed by Western blotting. The pro-apoptotic potentials of the main spiny and thornless OFI extract constituents were investigated structurally and mechanistically using protein–ligand docking and interaction profiling.\u0000 \u0000 \u0000 \u0000 Spiny OFI extract displayed a stronger cytotoxic effect than thornless OFI extract on K562 cells. In silico findings agreed with the pro-apoptotic action observed in vitro.\u0000 \u0000 \u0000 \u0000 Finally, our findings imply that OFI extracts cause apoptosis in K562 cells in order to have anti-cancer effects.\u0000","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"31 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141648317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Serin, Bağnu Orhan, Merve S. Say, H. Arslan, Sinemis Inal, B. B. Inal, Mehmet Şeneş
Abstract Objectives The ‘Rational Laboratory Use Project’ (RLUP) was launched in 2018 by the Department of Examination and Diagnosis Services under the General Directorate of Health Services of the Republic of Turkey’s Ministry of Health. In this study, we aimed to determine the rate of implementation of RLUP in medical biochemistry laboratories, and to contribute to new regulations by collecting the information and opinions of the laboratory experts participating the survey. Methods Thirty questions were uploaded to an online survey tool (SurveyMonkey®, San Mateo, ABD). The first five were descriptive for laboratories. Among the remaining 25 questions, one is open-ended and addresses the various topics encompassed by the project’s scope. Results The questionnaire was completed by 202 medical biochemistry specialists, of whom 82.12 % reported that they did not implement autoverification. 55.65 % defined consultations in Hospital Management Information System (HIMS), but; 70.49 % were not using it actively. 57.69 % of the participants answered, “I agree” to the statement “I think RLUP is feasible”. It was observed that the specialists tried to implement rational laboratory practices partially depending on their laboratory capacity, hospital administration and Laboratory Information Management System (LIMS). Conclusions Increasing clinicians’ awareness could increase the success of this project, which might provide more effective diagnosis and treatment for the patient. In our view, actively involving stakeholders of the information management system, which is not under the direct control of laboratory professionals, in the RLUP will accelerate the development of the project.
{"title":"Evaluation of the implementation of the rational use of laboratory tests in the clinical chemistry laboratory","authors":"H. Serin, Bağnu Orhan, Merve S. Say, H. Arslan, Sinemis Inal, B. B. Inal, Mehmet Şeneş","doi":"10.1515/tjb-2023-0132","DOIUrl":"https://doi.org/10.1515/tjb-2023-0132","url":null,"abstract":"Abstract Objectives The ‘Rational Laboratory Use Project’ (RLUP) was launched in 2018 by the Department of Examination and Diagnosis Services under the General Directorate of Health Services of the Republic of Turkey’s Ministry of Health. In this study, we aimed to determine the rate of implementation of RLUP in medical biochemistry laboratories, and to contribute to new regulations by collecting the information and opinions of the laboratory experts participating the survey. Methods Thirty questions were uploaded to an online survey tool (SurveyMonkey®, San Mateo, ABD). The first five were descriptive for laboratories. Among the remaining 25 questions, one is open-ended and addresses the various topics encompassed by the project’s scope. Results The questionnaire was completed by 202 medical biochemistry specialists, of whom 82.12 % reported that they did not implement autoverification. 55.65 % defined consultations in Hospital Management Information System (HIMS), but; 70.49 % were not using it actively. 57.69 % of the participants answered, “I agree” to the statement “I think RLUP is feasible”. It was observed that the specialists tried to implement rational laboratory practices partially depending on their laboratory capacity, hospital administration and Laboratory Information Management System (LIMS). Conclusions Increasing clinicians’ awareness could increase the success of this project, which might provide more effective diagnosis and treatment for the patient. In our view, actively involving stakeholders of the information management system, which is not under the direct control of laboratory professionals, in the RLUP will accelerate the development of the project.","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"313 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141686792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Kazdagli, E. Baris, Hasan Fehmi Ozel, Mustafa Ozbek
Abstract Objectives The variability in the time intervals between heartbeats, known as heart rate variability (HRV), serves as a reflection of the intricate interplay between the sympathetic and parasympathetic neural systems. While the potential asymmetric effects of the left and right branches of the vagus nerve remain uncertain, this study aims to investigate the impact of unilateral, bilateral, and atropine interventions on HRV parameters and choline levels within cardiac tissue. Methods 40 male adult Wistar albino rats were randomly assigned to the five groups (each n=8): sham-operated, atropine, right vagotomy, left vagotomy, and bilateral vagotomy. Heart rate variability (HRV) analyses were conducted, and the levels of total choline/acetylcholine in heart tissues were quantified. Statistical analyses were performed to assess the results. Results The bilateral vagotomy and atropine groups exhibited higher heart rates and high frequency power (HF), along with reduced low frequency power (LF). Total power (TP) remained relatively unchanged. In the bilateral vagotomy group, DFAα1 was significantly elevated while DFAα2 was reduced significantly. SD1 and SampEn were significantly lower in both the bilateral vagotomy and atropine groups. Notably, the right vagotomy group displayed significant changes primarily in the 15th minute, particularly in time-domain parameters, HF, TP, and SD1, with a significant increase observed in total choline levels. Conclusions Our results revealed that asymmetrical vagal innervation induces distinct effects on heart rate variability parameters and total choline/acetylcholine levels in heart tissues. Our findings suggest that compensatory hemodynamic recovery, possibly driven by contralateral vagal overactivity, may contribute to these observed results.
{"title":"Right vagotomy alters heart rate variability temporarily and increases total choline levels in rats","authors":"H. Kazdagli, E. Baris, Hasan Fehmi Ozel, Mustafa Ozbek","doi":"10.1515/tjb-2024-0046","DOIUrl":"https://doi.org/10.1515/tjb-2024-0046","url":null,"abstract":"Abstract Objectives The variability in the time intervals between heartbeats, known as heart rate variability (HRV), serves as a reflection of the intricate interplay between the sympathetic and parasympathetic neural systems. While the potential asymmetric effects of the left and right branches of the vagus nerve remain uncertain, this study aims to investigate the impact of unilateral, bilateral, and atropine interventions on HRV parameters and choline levels within cardiac tissue. Methods 40 male adult Wistar albino rats were randomly assigned to the five groups (each n=8): sham-operated, atropine, right vagotomy, left vagotomy, and bilateral vagotomy. Heart rate variability (HRV) analyses were conducted, and the levels of total choline/acetylcholine in heart tissues were quantified. Statistical analyses were performed to assess the results. Results The bilateral vagotomy and atropine groups exhibited higher heart rates and high frequency power (HF), along with reduced low frequency power (LF). Total power (TP) remained relatively unchanged. In the bilateral vagotomy group, DFAα1 was significantly elevated while DFAα2 was reduced significantly. SD1 and SampEn were significantly lower in both the bilateral vagotomy and atropine groups. Notably, the right vagotomy group displayed significant changes primarily in the 15th minute, particularly in time-domain parameters, HF, TP, and SD1, with a significant increase observed in total choline levels. Conclusions Our results revealed that asymmetrical vagal innervation induces distinct effects on heart rate variability parameters and total choline/acetylcholine levels in heart tissues. Our findings suggest that compensatory hemodynamic recovery, possibly driven by contralateral vagal overactivity, may contribute to these observed results.","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"11 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141700498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A brief history of hematology analyzers and recent advancements: the available testing wealth","authors":"Dogan Yucel, M. A. Serdar","doi":"10.1515/tjb-2024-0138","DOIUrl":"https://doi.org/10.1515/tjb-2024-0138","url":null,"abstract":"","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"20 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141334804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Objectives Raynaud’s phenomenon (RF) is a disease that causes discoloration of the fingers. The purpose of this study is to identify the molecular pathways in which genes related to RP illness are involved, as well as uncover the biological processes and molecular functions connected with those genes via the use of gene ontology (GO) analysis. Methods Genes associated with RP in the MalaCards Human Diseases database were detected. Twenty genes obtained from the MalaCards Human Diseases database were included in the study for gene ontology analysis via the STRING database. Accordingly, possible interactions between 20 genes were determined through STRING and network enrichment was performed. Results A significant enrichment by gene ontology enrichment analysis was detected in a subset of genes involved in biological processes including cellular response to luteinizing hormone stimulus, negative regulation of fibrinolysis, negative regulation of smooth muscle cell apoptotic process, plasminogen activation, cellular response to follicle-stimulating hormone stimulus. The assay for molecular function determined enrichment of a subset of genes in chemoattractant activity, growth factor activity, heparin binding, sulfur compound binding, growth factor receptor binding. Through the use of KEGG pathways, we were able to identify many molecular processes that contribute to RP, including the AGE-RAGE signaling pathway in diabetic complications, complement and coagulation cascades, fluid shear stress, atherosclerosis. Conclusions Some individuals may have a genetic predisposition to the onset of Raynaud’s phenomenon. Our data showed that it is associated with genes involved in vascular damage and fibrosis, especially in RP. Therefore, we can include RP disease in the group of vascular diseases.
{"title":"Determination of molecular pathways and gene ontology of genes associated with Raynaud’s phenomenon","authors":"Gözde Öztan","doi":"10.1515/tjb-2023-0197","DOIUrl":"https://doi.org/10.1515/tjb-2023-0197","url":null,"abstract":"Abstract Objectives Raynaud’s phenomenon (RF) is a disease that causes discoloration of the fingers. The purpose of this study is to identify the molecular pathways in which genes related to RP illness are involved, as well as uncover the biological processes and molecular functions connected with those genes via the use of gene ontology (GO) analysis. Methods Genes associated with RP in the MalaCards Human Diseases database were detected. Twenty genes obtained from the MalaCards Human Diseases database were included in the study for gene ontology analysis via the STRING database. Accordingly, possible interactions between 20 genes were determined through STRING and network enrichment was performed. Results A significant enrichment by gene ontology enrichment analysis was detected in a subset of genes involved in biological processes including cellular response to luteinizing hormone stimulus, negative regulation of fibrinolysis, negative regulation of smooth muscle cell apoptotic process, plasminogen activation, cellular response to follicle-stimulating hormone stimulus. The assay for molecular function determined enrichment of a subset of genes in chemoattractant activity, growth factor activity, heparin binding, sulfur compound binding, growth factor receptor binding. Through the use of KEGG pathways, we were able to identify many molecular processes that contribute to RP, including the AGE-RAGE signaling pathway in diabetic complications, complement and coagulation cascades, fluid shear stress, atherosclerosis. Conclusions Some individuals may have a genetic predisposition to the onset of Raynaud’s phenomenon. Our data showed that it is associated with genes involved in vascular damage and fibrosis, especially in RP. Therefore, we can include RP disease in the group of vascular diseases.","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"12 35","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141335100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Z. Javadova, Fatih Yanar, E. Aslan, G. Ozkara, Fidan Malikova, Onur Kılıcarslan, O. Ser, Ahmet Yildiz, O. Kucukhuseyin, O. Ozturk, Hülya YILMAZ AYDOĞAN
Abstract Objectives The peroxisome proliferator-activated receptor gamma (PPARG) C161T polymorphism (rs3856806) may be a risk factor for in-stent restenosis (ISR) due to its known associations with type 2 diabetes (T2DM), obesity, and coronary artery disease (CAD). This study aims to investigate the relationship between PPARG-C161T polymorphism and the risk of ISR, considering clinical features. Methods According to the results of coronary angiography, the patients who had undergone drug-eluting stent implantation were categorized into two groups: ISR (n=116) and non-ISR (n=265). The control group consisted of 140 healthy subjects with asymptomatic for CAD or any systemic disease. PPARG-C161T genotypes were determined using the real-time polymerase chain reaction melting curve analysis. Results T2DM, hypertension, and hyperlipidemia were observed as the main clinical features causing non-ISR and ISR. The 161-CC genotype was associated with an increased risk of ISR compared to both controls (p=0.014) and non-ISR patients (p=0.008). This difference remained statistically significant after multivariate analysis for non-ISR patients (p=0.003) but not for the ISR group. The prevalence of hypertension and hyperlipidemia was higher in ISR patients with T2DM than in non-ISR patients with T2DM (p=0.002 and p=0.009, respectively). Multivariate logistic regression analysis in subgroups based on the presence of T2DM showed that hypertension (p<0.001) was associated with ISR in patients with T2DM. Conclusions This study points out the association between the PPARG 161-CC genotype and the risk of ISR, which also means that the PPARG 161-T allele is protective against ISR. However, this effect could be divergent in the presence of the metabolic components of the restenosis phenotype, especially T2DM.
{"title":"Joint effects of PPARG-C161T (rs3856806) polymorphism and cardiovascular risk factors on restenosis risk after coronary stent implantation","authors":"Z. Javadova, Fatih Yanar, E. Aslan, G. Ozkara, Fidan Malikova, Onur Kılıcarslan, O. Ser, Ahmet Yildiz, O. Kucukhuseyin, O. Ozturk, Hülya YILMAZ AYDOĞAN","doi":"10.1515/tjb-2024-0021","DOIUrl":"https://doi.org/10.1515/tjb-2024-0021","url":null,"abstract":"Abstract Objectives The peroxisome proliferator-activated receptor gamma (PPARG) C161T polymorphism (rs3856806) may be a risk factor for in-stent restenosis (ISR) due to its known associations with type 2 diabetes (T2DM), obesity, and coronary artery disease (CAD). This study aims to investigate the relationship between PPARG-C161T polymorphism and the risk of ISR, considering clinical features. Methods According to the results of coronary angiography, the patients who had undergone drug-eluting stent implantation were categorized into two groups: ISR (n=116) and non-ISR (n=265). The control group consisted of 140 healthy subjects with asymptomatic for CAD or any systemic disease. PPARG-C161T genotypes were determined using the real-time polymerase chain reaction melting curve analysis. Results T2DM, hypertension, and hyperlipidemia were observed as the main clinical features causing non-ISR and ISR. The 161-CC genotype was associated with an increased risk of ISR compared to both controls (p=0.014) and non-ISR patients (p=0.008). This difference remained statistically significant after multivariate analysis for non-ISR patients (p=0.003) but not for the ISR group. The prevalence of hypertension and hyperlipidemia was higher in ISR patients with T2DM than in non-ISR patients with T2DM (p=0.002 and p=0.009, respectively). Multivariate logistic regression analysis in subgroups based on the presence of T2DM showed that hypertension (p<0.001) was associated with ISR in patients with T2DM. Conclusions This study points out the association between the PPARG 161-CC genotype and the risk of ISR, which also means that the PPARG 161-T allele is protective against ISR. However, this effect could be divergent in the presence of the metabolic components of the restenosis phenotype, especially T2DM.","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"31 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141340405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gülce Kiren, Ç. Severcan, Suzan Muratoğlu Severcan, Hatice Paşaoğlu
Abstract Objectives Excessive fructose consumption is recognized to elevate insulin resistance in animals and humans. In our study, we aimed to assess the possible consequences of curcumin (curc) treatment applied to rat models of fructose-induced insulin resistance on adenosine monophosphate-activated protein kinase (AMPK) and phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) pathways in skeletal muscle and adipose tissue. Methods We established four distinct rat groups: corn oil (negative control group), 20 % fructose (positive control group), 20 % fructose and 100 mg/kg curc (100 mg/kg curc group), and 20 % fructose and 200 mg/kg curc (200 mg/kg curc group). The ELISA method was used to determine serum insulin levels, an auto-analyzer was used to measure serum glucose levels, and homeostatic model assessment of insulin resistance (HOMA-IR) values were calculated. In the rat’s skeletal muscle and adipose tissues, the ELISA method was used to determine the following parameters: insulin receptor substrate-1 (IRS-1), phosphorylated insulin receptor substrate-1 (p-IRS-1), PI3K, phosphatidylinositol 3,4,5-trisphosphate (PIP3), phosphoinositide-dependent kinases (PDK-1), phosphorylated Akt (p-Akt), AMPK and glucose transporter type 4 (GLUT4) levels. Results The positive control group exhibited a significant increase in serum glucose, insulin, and HOMA-IR levels, confirming the establishment of the insulin resistance model. In the curcumin dose groups, these values significantly decreased. Additionally, compared to the positive control groups, curcumin dose groups demonstrated a significant increase in the parameters of the Akt/PI3K pathway, AMPK activation, and GLUT4 levels in skeletal muscle and adipose tissues. Conclusions We observed that curcumin demonstrates potential ameliorative effects on the insulin signaling pathway through PI3K/Akt and AMPK pathways.
{"title":"The effect of curcumin on PI3K/Akt and AMPK pathways in insulin resistance induced by fructose","authors":"Gülce Kiren, Ç. Severcan, Suzan Muratoğlu Severcan, Hatice Paşaoğlu","doi":"10.1515/tjb-2024-0027","DOIUrl":"https://doi.org/10.1515/tjb-2024-0027","url":null,"abstract":"Abstract Objectives Excessive fructose consumption is recognized to elevate insulin resistance in animals and humans. In our study, we aimed to assess the possible consequences of curcumin (curc) treatment applied to rat models of fructose-induced insulin resistance on adenosine monophosphate-activated protein kinase (AMPK) and phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) pathways in skeletal muscle and adipose tissue. Methods We established four distinct rat groups: corn oil (negative control group), 20 % fructose (positive control group), 20 % fructose and 100 mg/kg curc (100 mg/kg curc group), and 20 % fructose and 200 mg/kg curc (200 mg/kg curc group). The ELISA method was used to determine serum insulin levels, an auto-analyzer was used to measure serum glucose levels, and homeostatic model assessment of insulin resistance (HOMA-IR) values were calculated. In the rat’s skeletal muscle and adipose tissues, the ELISA method was used to determine the following parameters: insulin receptor substrate-1 (IRS-1), phosphorylated insulin receptor substrate-1 (p-IRS-1), PI3K, phosphatidylinositol 3,4,5-trisphosphate (PIP3), phosphoinositide-dependent kinases (PDK-1), phosphorylated Akt (p-Akt), AMPK and glucose transporter type 4 (GLUT4) levels. Results The positive control group exhibited a significant increase in serum glucose, insulin, and HOMA-IR levels, confirming the establishment of the insulin resistance model. In the curcumin dose groups, these values significantly decreased. Additionally, compared to the positive control groups, curcumin dose groups demonstrated a significant increase in the parameters of the Akt/PI3K pathway, AMPK activation, and GLUT4 levels in skeletal muscle and adipose tissues. Conclusions We observed that curcumin demonstrates potential ameliorative effects on the insulin signaling pathway through PI3K/Akt and AMPK pathways.","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"1 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141341143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Levent Deniz, H. Aral, Özlem Akdoğan, H. Arslan, E. Yiğit
We aimed to investigate the relationship among proprotein convertase subtilisin/kexin type 9 (PCSK9), adropin levels, inflammation, and sleep variables in non-diabetic males with severe obstructive sleep apnea (OSA). This cross-sectional study included adults aged 18 to 65 who underwent polysomnography due to sleep problems between July 2019 and August 2020. Participants were grouped based on their apnea-hypopnea index (AHI). We included 32 males with simple snoring (AHI<5 events/h) as the controls and 48 males with severe OSA (AHI≥30 events/h). Furthermore, patients with severe OSA were divided into two groups based on body mass index (BMI), resulting in three groups in total. Adropin and PCSK9 were analyzed using the enzyme-linked immunosorbent assay method. In severe OSA with BMI≥30 kg/m2, compared to the controls, blood pressure values, interleukin-6 (IL-6), white blood cell (WBC) count, systemic inflammation response index, neutrophil, monocyte counts were found to be higher, but adropin/BMI, adropin/waist circumference, adropin/neck circumference were significantly lower. Adropin/BMI had the highest correlation coefficient with IL-6. Although there was no significant difference in PCSK9 levels among the groups, PCSK9 was independently correlated with the WBC and its subsets. Our study is of clinical importance as it is the first to show a relationship between PCSK9 and inflammation markers in severe OSA. Also, this study demonstrated the potential value of adropin, in combination with BMI, as a valuable indicator for assessing inflammation and OSA severity.
我们的目的是研究患有严重阻塞性睡眠呼吸暂停（OSA）的非糖尿病男性患者中，丙蛋白转换酶亚基酶/kexin 9型（PCSK9）、阿托品水平、炎症和睡眠变量之间的关系。 这项横断面研究纳入了2019年7月至2020年8月期间因睡眠问题接受多导睡眠图检查的18至65岁成年人。根据呼吸暂停-低通气指数（AHI）对参与者进行分组。我们将32名单纯打鼾（AHI<5次/小时）的男性作为对照组，将48名严重OSA（AHI≥30次/小时）的男性作为对照组。此外，根据体重指数（BMI）将严重 OSA 患者分为两组，共三组。采用酶联免疫吸附法分析阿托品和PCSK9。 与对照组相比，BMI≥30 kg/m2的重度OSA患者的血压值、白细胞介素-6（IL-6）、白细胞计数、全身炎症反应指数、中性粒细胞、单核细胞计数均高于对照组，但阿托品/BMI、阿托品/腰围、阿托品/颈围均显著低于对照组。阿托品/体重指数与 IL-6 的相关系数最高。虽然各组间的 PCSK9 水平无明显差异，但 PCSK9 与白细胞及其亚群独立相关。 我们的研究首次显示了严重 OSA 患者 PCSK9 与炎症指标之间的关系，因此具有重要的临床意义。此外，这项研究还证明了阿托品与体重指数相结合作为评估炎症和 OSA 严重程度的重要指标的潜在价值。
{"title":"Evaluation of adropin indices and PCSK9 in non-diabetic men with severe obstructive sleep apnea","authors":"Levent Deniz, H. Aral, Özlem Akdoğan, H. Arslan, E. Yiğit","doi":"10.1515/tjb-2023-0283","DOIUrl":"https://doi.org/10.1515/tjb-2023-0283","url":null,"abstract":"\u0000 \u0000 \u0000 We aimed to investigate the relationship among proprotein convertase subtilisin/kexin type 9 (PCSK9), adropin levels, inflammation, and sleep variables in non-diabetic males with severe obstructive sleep apnea (OSA).\u0000 \u0000 \u0000 \u0000 This cross-sectional study included adults aged 18 to 65 who underwent polysomnography due to sleep problems between July 2019 and August 2020. Participants were grouped based on their apnea-hypopnea index (AHI). We included 32 males with simple snoring (AHI<5 events/h) as the controls and 48 males with severe OSA (AHI≥30 events/h). Furthermore, patients with severe OSA were divided into two groups based on body mass index (BMI), resulting in three groups in total. Adropin and PCSK9 were analyzed using the enzyme-linked immunosorbent assay method.\u0000 \u0000 \u0000 \u0000 In severe OSA with BMI≥30 kg/m2, compared to the controls, blood pressure values, interleukin-6 (IL-6), white blood cell (WBC) count, systemic inflammation response index, neutrophil, monocyte counts were found to be higher, but adropin/BMI, adropin/waist circumference, adropin/neck circumference were significantly lower. Adropin/BMI had the highest correlation coefficient with IL-6. Although there was no significant difference in PCSK9 levels among the groups, PCSK9 was independently correlated with the WBC and its subsets.\u0000 \u0000 \u0000 \u0000 Our study is of clinical importance as it is the first to show a relationship between PCSK9 and inflammation markers in severe OSA. Also, this study demonstrated the potential value of adropin, in combination with BMI, as a valuable indicator for assessing inflammation and OSA severity.\u0000","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"78 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141268456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：